While the distribution in terms of age was aligned with published findings from the broader US CCA population20 and real-world analysis of US patients with FGFR2 fusions/rearrangements and advanced CCA, (median age at initial diagnosis, 63 years),11 the proportion of females was lower in our real-world study than that published in other real-world analyses of patients with CCA with FGFR2 genetic aberrations (50.8% vs approximately 63%).21,22. This evidence concerns the gene FGFR2 and cholangiocarcinoma.